Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Idenix Shares Rise on Positive Hepatitis C Study Results


Investors hope the company has a next-generation treatment for the virus. The new data will fuel more takeover talk.

MINYANVILLE ORIGINAL Shares of Idenix (IDIX) are rising after the company said an experimental hepatitis C drug was effective in a mid-stage study.

The stock rose 12% to $10.52 in early trading Wednesday. The shares almost doubled in the past 12 months as investors hope Idenix will be among the winners in developing a better treatment for the liver-destroying virus.

The company said its drug candidate IDX184 worked in combination with older drugs and it hopes to test the experimental treatment without the older injected therapy interferon. One of the goals for the next-generation of hepatitis C treatments is to provide an all-oral regimen without interferon, which has serious side effects. Idenix also reported positive clinical results validating another experimental drug, IDX719, which it will test with its other hepatitis therapy.

Idenix is competing in a crowded field. Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Vertex Pharmaceuticals (VRTX), Merck (MRK), Abbott Laboratories (ABT), Roche (RHHBY), and Achillion Pharmaceuticals (ACHN) are among the companies developing new treatments.

It's important to note that none of these next-generation drugs are even close to entering the market. And a big part of Idenix's appeal is that it would appear to be a potential takeover candidate for another large drug company that wants to jump into the competition.

Idenix shares spiked after Bristol-Myers announced in January that it was taking over hepatitis drug developer Inhibitex. (See Bristol-Myers Enters Hepatitis Drug Race With $2.5 Billion Takeover of Inhibitex.) Prior to the Bristol-Myers deal, Gilead made an almost $11 billion wager on hepatitis drug maker Pharmasset.

Novartis (NVS) remains a large shareholder in Idenix and would have a say in any acquisition.

Former development partner Novartis walked away from IDX184 in 2009, returning rights for the drug back to Idenix. Once a majority owner, Novartis held almost 31% of Idenix's common stock as of March, according to a securities filing. Novartis executive Robert Pelzer sits on Idenix's seven-member board and the big drug maker has the right to appoint another director following the recent resignation of company exec Brian Goff.

Idenix's announcement Wednesday is expected to keep investors' interest in the company, particularly if it begins studies to test its drug without interferon later this year. Study results announced Wednesday will be presented at an upcoming medical conference, the company said.

"We expect relatively busy news flow and greater interest in the story in the coming year," Leerink Swann analyst Howard Liang says in a note Wednesday.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos